Treatment of Experimental Myocarditis via Modulation of the Renin-Angiotensin System

Author(s): Melvin D. Daniels, Kenneth V. Hyland, David M. Engman

Journal Name: Current Pharmaceutical Design

Volume 13 , Issue 13 , 2007

Become EABM
Become Reviewer


The renin-angiotensin system is primarily responsible for regulating vascular tone. Drugs that inhibit this pathway, angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists, are widely used to treat hypertension and a variety of cardiomyopathies. Recent studies have shown that, in addition to reducing blood pressure, these drugs also modulate inflammation, adhesion molecule expression, and fibrosis. To assess the therapeutic potential of these inhibitory agents for the treatment of inflammatory heart disease, the drugs have been tested in experimental models of infectious and autoimmune myocarditis. This review summarizes the results of studies examining the efficacy of angiotensin converting enzyme inhibitors and angiotensin receptor antagonists for the treatment of mouse models of virusinduced and parasite-induced myocarditis, as well as autoimmune cardiomyopathy. The collective results strongly support the use of renin-angiotensin modulation for the treatment of myocarditis. Importantly, this therapeutic approach seems to downregulate autoimmunity without causing immune suppression which may enhance the survival of the diseaseinitiating infectious agent.

Keywords: Angiotensin converting enzyme, angiotensin, renin-angiotensin system, immunity, myocarditis, autoimmunity, cardiac

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2007
Page: [1299 - 1305]
Pages: 7
DOI: 10.2174/138161207780618812
Price: $65

Article Metrics

PDF: 3